Hypertension and Cardiovascular Risk Factors

Novartis

Status and phase: Completed; Phase 4

Conditions: HYPERTENSION

Treatments: Drug: VALSARTAN+HYDROCHLOROTHIAZIDE

Study type: Interventional

Funder types: Industry

Identifiers

NCT00171782

CVAH631BCO02

Details and patient eligibility

About

A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.

Enrollment: 76 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Patients who give consent
• Men and women 18 to 80 years of age
• Patients with hypertension (systolic >159 mm, diastolic >100 mm)
• Patients meeting laboratory criteria

Exclusion criteria

• • Pregnant women
• Women not using approved contraception methods
• Secondary hypertension

Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)